APTO 8-K: Exhibit 99.1 Press Release and Inline XBRL Exhibit 104

Rhea-AI Filing Summary

Aptose Biosciences Inc. disclosed in a Form 8-K that on August 13, 2025 it issued a press release reporting its results of operations and financial condition, which is furnished as Exhibit 99.1. The filing states the press release is furnished under General Instruction B.2 and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated. The Form 8-K also provides a cover page interactive XBRL file as Exhibit 104. The report is signed by William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

Insights

Securities Analyst

TL;DR: Routine 8-K reporting a press release on results; no financial details included, limiting investor assessment.

This 8-K notifies investors that a press release concerning results of operations and financial condition was issued and is attached as Exhibit 99.1. The company explicitly states the exhibit is furnished rather than "filed," which limits its incorporation by reference and legal implications under Section 18. Because the substance of the press release is not included in the 8-K text provided, there is insufficient information here to evaluate revenue, earnings, guidance, or balance sheet changes. Impact: not material based on the filing alone.

Corporate Governance Expert

TL;DR: The filing follows standard disclosure protocol; the "furnished" designation and Inline XBRL exhibit are the primary governance and compliance elements.

The Form 8-K follows customary formatting: it identifies Exhibit 99.1 (press release) and Exhibit 104 (cover page interactive XBRL). The explicit statement that the press release is furnished under General Instruction B.2 is a standard legal caveat to limit Section 18 liability and incorporation by reference. The signature of the CEO, William G. Rice, Ph.D., completes the required attestation. From a governance perspective, this filing is procedural and does not, by itself, indicate any change in control, officer departures, or other corporate governance events.

False000088236100008823612025-08-132025-08-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 13, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit Number		Description
99.1		Press Release dated August 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: August 13, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer

FAQ

What did Aptose (APTO) disclose in this 8-K filing?

The company disclosed that on August 13, 2025 it issued a press release regarding its results of operations and financial condition, furnished as Exhibit 99.1 to the Form 8-K.

Is the press release attached to the 8-K considered "filed" with the SEC?

No. The filing states that the press release is furnished under General Instruction B.2 and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly stated.

What exhibits were included with Aptose's 8-K?

The Form 8-K lists Exhibit 99.1 (Press Release dated August 13, 2025) and Exhibit 104 (Cover Page Interactive Data File embedded within the Inline XBRL document).

Does the 8-K include the press release text or financial statements?

The 8-K text provided notes the press release is attached as Exhibit 99.1, but the filing text itself does not include detailed financial statements or the substantive press release content.

Who signed the Form 8-K for Aptose Biosciences?

The report is signed by William G. Rice, Ph.D., who is identified as Chairman, President, and Chief Executive Officer.